Response: We thank commenters for their support of our proposal
Why The Results Differ From Previous Clinical Trials Earlier randomized trials including the STEP 1 extension for semaglutide and the SURMOUNT-4 trial for tirzepatide found that patients who stopped these medications regained a significant portion of their lost weight within a year
Published Program Characteristics Relevant to Telehealth GLP-1 Evaluation Based on the company's published structure, consumers researching telehealth GLP-1 programs may note the following characteristics of the MEDVi model: Fully online process: The company describes its process as 100% online from initial health evaluation through clinical consultation to medication delivery
In individuals with pre-existing gastrointestinal conditions such as inflammatory bowel disease, coeliac disease, or irritable bowel syndrome, introducing any new supplement may temporarily affect bowel habits as the digestive system adapts
GLP-1 has several actions that are directly relevant to weight and metabolic health: Reduces appetite by acting on brain centres that regulate hunger
This essential peptide can be found in various foods and supplements
